aficamten
Selected indexed studies
- Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. (N Engl J Med, 2024) [PMID:38739079]
- Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. (N Engl J Med, 2025) [PMID:40888697]
- Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. (Nat Cardiovasc Res, 2024) [PMID:39196032]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. (2024) pubmed
- Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. (2025) pubmed
- Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. (2024) pubmed
- Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. (2023) pubmed
- Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. (2024) pubmed
- Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. (2024) pubmed
- Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. (2024) pubmed
- Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. (2025) pubmed
- Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. (2025) pubmed
- Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. (2024) pubmed